Rock bottom interest rates will likely boost key biotechnology stocks, a fund manager told CNBC on Wednesday. But complex new health care implementation may cast a pall on the shares of health management organizations.
"As a group, biotech is probably the place to be this year because low interest rates are supportive of at least some of the macro stuff," said Les Funtleyder, president of the investment advisory arm of Poliwogg, an asset manager. "Low interest rates are supportive of capital consuming sectors like biotech."